UBS raised the firm’s price target on Bruker (BRKR) to $43 from $40 and keeps a Neutral rating on the shares. Despite the 2025 guidance cut, bookings are mostly “constructive,” the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target raised to $45 from $40 at Barclays
- Bruker Corporation Reports Q3 2025 Financial Results
- Cautious Optimism for Bruker: Hold Rating Amid Uncertain Sustained Growth
- Bruker upgraded to Hold from Sell at Nephron Research
- Morning Movers: Kenvue surges, Kimberly-Clark sinks after tie up